# US 2008/0305103 A1 · Intraocular pressure-regulated early genes and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2008/0305103 A1
- Document ID: US20080305103A1
- Status: Published application
- Kind: A1
- Application number: 12/154,396
- Filed: 2008-05-22
- Published: 2008-12-11
- Earliest claimed: 2005-11-22
- Assignees: McGill University
- Inventors: H. Uri Saragovi
- Web page: https://patentgrep.com/patent/US20080305103A1

## CPC

- C07K 16/18: against material from animals or humans
- A61P 27/06: Antiglaucoma agents or miotics
- C07K 14/47: from mammals
- C07K 16/30: from tumour cells
- G01N 33/5308: {for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites}
- A61K 2039/505: {comprising antibodies}
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- G01N 2800/168: Glaucoma
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present invention relates to methods to treat glaucoma and glaucoma-related conditions through the regulation of changes in gene expression that are mediated by high intraocular pressure or α2 macgroglobulin administration. Glaucoma, retinal ganglion cell (RGC) death and chronic ocular hypertension are treated using pharmaceutical compositions which comprise substances that inhibit the expression or activity of intraocular pressure-regulated early genes (IPREGs) or their gene products that are up-regulated by high intraocular pressure or α2 macgroglobulin administration and/or which increase the expression or activity of IPREGs or their gene products that are down-regulated by high intraocular pressure or α2 macgroglobulin administration. The invention also relates to methods of identifying an IPREG and methods to test for chronic ocular degeneration and the onset of RGC stress in an individual by measuring the expression level of IPREG proteins.

## Claims

### Claim 1

A method of treating glaucoma in a mammal in need thereof comprising administering to the mammal an effective amount of a composition that inhibits the expression or activity of α2 macroglobulin.

### Claim 2

(canceled)

### Claim 3 (depends on 1)

The method of claim 1 wherein the composition comprises one or more selected from the group consisting of small interfering RNAs, antisense oligonucleotides, neutralizing antibodies, small molecules, recombinant gene expression vectors, recombinant gene viral vectors, synthetic peptides, recombinant polypeptides, peptidomimetics and inhibitors of the regulatory regions of the IPREGs.

### Claim 4 (depends on 3)

The method of claim 3 wherein the composition is administered by at least one method selected from the group consisting of intraocular injection, topical conjunctival application, topical corneal application and a mechanical delivery device.

### Claim 5

(canceled)

### Claim 6 (depends on 4)

The method of claim 4 wherein the α2 macroglobulin activity is inhibited by antagonizing α2 macroglobulin receptors.

### Claim 7 (depends on 6)

The method of claim 6 further comprising administering one or more intraocular pressure-normalizing drugs.

### Claim 8 (depends on 7)

The method of claim 7 wherein the one or more intraocular pressure-normalizing drugs are selected from the group consisting of non-selective-adrenoceptor blockers, selective-adrenoceptor blockers, prostaglandins, carbonic anhydrase inhibitors, adrenergic agonists and miotics.

### Claim 9 (depends on 8)

The method of claim 8 wherein the intraocular pressure-normalizing drug administered is betaxolol.

### Claim at position 10

10-16. (canceled)

### Claim 17

A method of preventing retinal ganglion cell (RGC) death mediated by high intraocular pressure (IOP) comprising administering to an individual in need thereof an effective amount of a composition that inhibits the expression or activity of α2 macroglobulin.

### Claim 18 (depends on 17)

The method of claim 17 further comprising administering one or more intraocular pressure-normalizing drugs.

### Claim 19

A method of preventing chronic ocular degeneration in a mammal in need thereof comprising administering to the mammal an effective amount of a composition that inhibits the expression or activity of α2 macroglobulin.

### Claim 20 (depends on 19)

The method of claim 19 further comprising administering one or more intraocular pressure-normalizing drugs.

### Claim 21

A method of testing for chronic ocular degeneration in a patient comprising:
a.) measuring the expression level of α macroglobulin in the aqueous humor of the patient; and
b.) comparing the expression level to that of the α macroglobulin in individuals with normal ocular function,
wherein a higher expression level of α2 macroglobulin as compared to the expression level of the α macroglobulin in individuals with normal ocular function indicates that the patient has chronic ocular degeneration.

### Claim 22

A method of testing for the onset of RGC stress in a patient comprising:
a.) measuring the expression level of one α macroglobulin in the aqueous humor of the patient at an initial time point;
b.) measuring the expression level of α macroglobulin in the aqueous humor of the patient at later time point; and
c.) comparing the expression level of the α macroglobulin measured at the initial time point to that measured at the later time point,
wherein a higher expression level of α2 macroglobulin in the patient indicates the onset of RGC stress in the patient.

### Claim 23

A method of identifying an intraocular pressure-regulated early gene (IRPEG) comprising:
a) determining whether expression of a gene is altered by ocular hypertension, wherein expression of the gene is not altered by retinal ganglion cell (RGC) damage;
b) determining whether expression of the gene is altered early after the onset of ocular hypertension;
c) determining whether the altered expression of the gene is sustained after onset of ocular hypertension or glaucoma; and
d) determining whether expression of the gene remains altered after ocular hypertension is reduced.

### Claim 24 (depends on 23)

The method of claim 23 further comprising determining the effect of the gene identified on RGC death, glaucoma in vivo, or both.

### Claim 25 (depends on 23)

An IPREG identified by the method of claim 23.

### Claim at position 20

-35. (canceled)
